IGC Pharma Expands Phase 2 CALMA Alzheimer’s Trial
POTOMAC, Md., Feb. 9, 2026 — IGC Pharma, Inc. announced the expansion of its ongoing Phase 2 CALMA clinical...
Alzheimer’s Disease
TML-6 Advances to Global Phase 2 Alzheimer’s Trials
TAINAN, Taiwan, Feb. 9, 2026 — MerryLife Biomedical Inc. announced positive Phase 1 clinical findings for TML-6, its investigational...
FDA Clears Neurophet AQUA AD Plus in Alzheimer’s AI
Seoul, South Korea — February 6, 2026 Neurophet has announced that the U.S. Food and Drug Administration (FDA) has...
Tau Immunotherapy AADvac1 Enters Landmark AD Trial
SAN FRANCISCO, Calif., Feb. 4, 2026 — Axon Neuroscience announced that its active tau immunotherapy AADvac1 has been selected...
Fujirebio Launches Automated pTau217 CSF Assay for Alzheimer’s Research
Tokyo, Japan – January 28, 2026 – Fujirebio, a global leader in in vitro diagnostics and part of H.U....
FDA Accepts LEQEMBI sBLA, Expanding At-Home Alzheimer’s Therapy
Tokyo & Cambridge, Massachusetts, January 25, 2026 — Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food...
Medicare Expands Access to Early Alzheimer’s Therapies
FAIRFAX, Va., January 22, 2026 — Re:Cognition Health announced that Medicare coverage is now available for FDA-approved amyloid-targeting therapies...
Finger-Prick Blood Test Could Enable Early Alzheimer’s Diagnosis
London, January 19, 2026 — Scientists from a major international collaboration led by LifeArc and the Global Alzheimer’s Platform...
China Adds LEQEMBI to Insurance List for Early Alzheimer’s
TOKYO and CAMBRIDGE, Mass., December 8, 2025 — Eisai Co., Ltd. and Biogen Inc. announced that LEQEMBI® (lecanemab), an...
Zervimesine Phase 3 Plan Advances Alzheimer’s Drug Strategy
Purchase, N.Y. — December 1, 2025 — Cognition Therapeutics has unveiled its Phase 3 registrational plan for Zervimesine (CT1812)...